CV Sciences, Inc. (CVSI): Depreciation & Amortization
$192.0K
Year ended 2025-12-31
$97.0K
Trailing 12 months to 2026-06-30
-42.2%
3-year compound annual growth
-26.1%
5-year compound annual growth
-15.3%
10-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $192.0K | -42.5% | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | $334.0K | +42.1% | 2026-03-26, From 2024-01-01 |
| 2023-12-31 | $235.0K | -76.3% | 2025-03-27, From 2023-01-01 |
| 2022-12-31 | $992.0K | -14.0% | 2024-03-29, From 2022-01-01 |
| 2021-12-31 | $1.15M | +32.2% | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | $872.0K | +21.8% | 2022-04-04, From 2020-01-01 |
| 2019-12-31 | $716.0K | +38.0% | 2021-03-19, From 2019-01-01 |
| 2018-12-31 | $519.0K | +183.6% | 2020-03-30, From 2018-01-01 |
| 2017-12-31 | $183.0K | -82.6% | 2019-03-12, From 2017-01-01 |
| 2016-12-31 | $1.05M | +4.0% | 2018-03-30, From 2016-01-01 |
| 2015-12-31 | $1.01M | +8.4% | 2017-03-31, From 2015-01-01 |
| 2014-12-31 | $933.6K | +21.7% | 2016-04-14, From 2014-01-01 |
| 2013-12-31 | $767.3K | n/a | 2015-03-31, From 2013-01-01 |
| 2012-12-31 | $0 | n/a | 2014-03-28, From 2012-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $192.0K | -42.5% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $4.51M | +51.3% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $1.90M | -34.5% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $600.0K | +20.0% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $39.0K | +77.3% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $1.71M | -3.4% |
| uniQure N.V. (QURE) | 2025-12-31 | $14.76M | +16.8% |
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | $1.91M | +0.7% |
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $109.0K | -53.2% |
Compare CVSI, PYXS, TNXP, EVMN side by side · Screen every company in Pharmaceutical Preparations ↗